Our Story
Founded in 2011, LePure Biotech specializes in single-use systems and consumables for the biopharmaceutical industry. We offer reliable and high-quality bioprocessing solutions with vertically integrated manufacturing from in-house film extrusion to final product assembly, ensuring quality, consistency, and control.
With R&D and commercial operations across the U.S., South China, and Korea, our global footprint enables faster lead times and greater responsiveness, keeping your projects on track in today’s fast-paced market.
Company Highlights
4
Key Consumables
200+
Patents
3000+
Customers In 30+ countries
14yrs
Business in bioprocess products and services
Our Journey
2011
Founded in 2011, the company began by developing single-use bioprocess technologies to serve biotech and pharmaceutical clients.
2015
LePure Biotech launched its self-developed single-use process equipment.
2019
LePure Biotech participated in the national research project on cottonseed cultivation aboard the Chang’e-4 space station and was honored as a Shanghai Specialized and Innovative Enterprise.
2021
Achieved a significant milestone with the establishment of its state-of-the-art US-based R&D center in Massachusetts. Additionally, the company garnered substantial investments from top-tier investors such as Legend Capital and Hillhouse China, further fortifying its industry presence.
2022
LePure Biotech’s strategic acquisitions of Geshi Filter and QuaCell Biotech have transformed it into a leading biotechnology solutions provider, seamlessly integrating pharmaceutical filtration technology and cell culture development expertise. The company has gained the support of top-tier investors such as NOVO, GA, and GS, while also achieving dual ISO13485 and ISO9001 certifications. LePure Biotech’s outstanding growth was further acknowledged with the Shanghai Hundreds Growing Business award, cementing its position as an industry leader.
2023
Acquisition of Sterist and the subsequent integration of comprehensive clean management solutions have significantly broadened the company’s business portfolio.
2024
LePure Biotech acquired Fittinn to strengthen its capabilities in cell cultivation solutiosn and Schbio Biotech to expand into early drug discovery.
Bioprocess Solution
Our production process enables us to optimize costs without compromising on the quality of our single-use equipment and consumables. LePure Biotech remains dedicated to delivering cost-effective solutions without compromising the cutting-edge technology and reliability that we are renowned for.